DEA Hearing on Cannabis Rescheduling Advances With Witness Schedule Set
Administrative law judge finalizes testimony lineup for landmark marijuana rescheduling proceedings beginning next week, marking critical juncture for federal policy.
The Drug Enforcement Administration's administrative law judge has established the witness testimony schedule for cannabis rescheduling hearings set to commence next week, advancing the most consequential federal marijuana policy review in decades. The proceedings represent a pivotal moment for the cannabis industry as stakeholders present evidence regarding the potential move of marijuana from Schedule I to Schedule III under the Controlled Substances Act.
The hearings follow months of regulatory review after the Department of Health and Human Services recommended rescheduling based on scientific analysis of cannabis's medical utility and abuse potential. Moving marijuana to Schedule III would maintain federal prohibition but acknowledge accepted medical use, fundamentally altering the regulatory framework governing cannabis businesses and research institutions.
For publicly traded cannabis companies, rescheduling carries profound financial implications. Schedule III classification would eliminate the punitive 280E tax provision that prevents cannabis businesses from deducting standard business expenses, potentially improving margins across the sector. Multi-state operators like Curaleaf (CURLF), Trulieve (TCNNF), and Green Thumb Industries (GTBIF) could see immediate earnings improvements as operational costs become fully deductible.
The testimony schedule indicates the DEA is conducting a thorough review process, with witnesses expected to address medical research, public health considerations, and regulatory implementation challenges. Industry observers note that while rescheduling wouldn't legalize recreational cannabis federally, it would remove significant barriers to banking services, interstate commerce, and institutional investment that have constrained sector growth.
The hearings unfold as cannabis stocks trade near multi-year lows despite growing state-level legalization and improving operational metrics across major operators. Investors remain cautious about federal policy developments, but rescheduling represents the most realistic near-term catalyst for regulatory reform. The administrative process could extend several months, with the final decision ultimately resting with DEA Administrator Anne Milgram, though the agency rarely contradicts HHS medical recommendations on scheduling matters.